The clinical trial sponsored by CAR-T (Shanghai) Biotechnology Co., Ltd. aims to evaluate the safety and efficacy of dental pulp mesenchymal cell injections in treating severe depressive disorder. Given the increasing prevalence of depression globally and the limitations of current antidepressant therapies, this innovative approach could position CAR-T as a pioneer in the regenerative medicine space for mental health. The trial's design includes a positive control (fluoxetine), which may enhance credibility but also introduces competition from established antidepressants. The market for depression treatments is substantial, with a growing demand for novel therapies, particularly those that address treatment-resistant cases. Successful outcomes could lead to significant commercial opportunities, including partnerships, licensing, and potential market exclusivity, depending on the regulatory landscape and patent protections.